OMER - Omeros: Despite Its Promise The CRL Is A Huge Obstacle February, 21 2022 07:49 AM Omeros Corporation Omeros was handed a CRL for narsoplimab. The lack of clarity surrounding the CRL is disconcerting. I will stay on the sidelines despite the seemingly attractive price. For further details see: Omeros: Despite Its Promise, The CRL Is A Huge Obstacle